Traders Purchase Large Volume of Call Options on Juno Therapeutics (JUNO)

Juno Therapeutics Inc (NASDAQ:JUNO) saw unusually large options trading activity on Thursday. Stock traders bought 18,161 call options on the company. This represents an increase of 1,208% compared to the average daily volume of 1,388 call options.

Juno Therapeutics (JUNO) opened at $67.81 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.77 and a current ratio of 4.77. The firm has a market cap of $8,148.52, a P/E ratio of -20.06 and a beta of 2.32. Juno Therapeutics has a 1-year low of $19.07 and a 1-year high of $74.35.

Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.07. The firm had revenue of $44.80 million during the quarter, compared to analyst estimates of $18.12 million. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The business’s quarterly revenue was up 115.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.57) EPS. sell-side analysts anticipate that Juno Therapeutics will post -4.02 earnings per share for the current year.

In related news, Director Richard Klausner sold 12,724 shares of Juno Therapeutics stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $48.21, for a total value of $613,424.04. Following the completion of the sale, the director now directly owns 741,499 shares in the company, valued at approximately $35,747,666.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Robert Azelby sold 29,131 shares of Juno Therapeutics stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $68.61, for a total transaction of $1,998,677.91. Following the completion of the sale, the executive vice president now owns 73,330 shares of the company’s stock, valued at $5,031,171.30. The disclosure for this sale can be found here. Insiders sold a total of 365,337 shares of company stock valued at $17,540,499 over the last quarter. 15.08% of the stock is owned by company insiders.

Large investors have recently bought and sold shares of the company. Teachers Advisors LLC increased its holdings in shares of Juno Therapeutics by 15.4% during the 2nd quarter. Teachers Advisors LLC now owns 74,255 shares of the biopharmaceutical company’s stock valued at $2,219,000 after purchasing an additional 9,890 shares in the last quarter. DekaBank Deutsche Girozentrale increased its holdings in shares of Juno Therapeutics by 27.9% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 61,900 shares of the biopharmaceutical company’s stock valued at $1,712,000 after purchasing an additional 13,500 shares in the last quarter. Northern Trust Corp increased its holdings in shares of Juno Therapeutics by 11.8% during the 2nd quarter. Northern Trust Corp now owns 382,631 shares of the biopharmaceutical company’s stock valued at $11,438,000 after purchasing an additional 40,468 shares in the last quarter. Candriam Luxembourg S.C.A. purchased a new position in shares of Juno Therapeutics during the 3rd quarter valued at approximately $5,428,000. Finally, Sivik Global Healthcare LLC purchased a new position in shares of Juno Therapeutics during the 3rd quarter valued at approximately $2,467,000. 69.94% of the stock is owned by hedge funds and other institutional investors.

JUNO has been the subject of a number of recent research reports. Citigroup lowered shares of Juno Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday. Raymond James Financial reissued a “buy” rating on shares of Juno Therapeutics in a research report on Wednesday. Cowen reissued a “buy” rating on shares of Juno Therapeutics in a research report on Friday, November 3rd. Zacks Investment Research lowered shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Finally, Wells Fargo & Co lowered shares of Juno Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, December 12th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $47.26.

TRADEMARK VIOLATION WARNING: “Traders Purchase Large Volume of Call Options on Juno Therapeutics (JUNO)” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/01/21/traders-purchase-large-volume-of-call-options-on-juno-therapeutics-juno.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply